IGHE and allergic disease: Basophil‐related biologics such as IgE (Omalizumab), IL‐4 receptor α chain (Dupilumab), IL‐5 (Reslizumab and Mepolizumab), IL‐5 receptor α chain (Benralizumab) and IL‐13 (Tralokinumab) have been approved by the US Food and Drug Administration (FDA) for the treatment of allergic diseases (Table 1, Figure 1).